标题:Off-label use of tacrolimus in children with glomerular disease: Effectiveness, safety and pharmacokinetics
作者:Hao, Guo-Xiang; Song, Lin-Lin; Zhang, Dong-Feng; Su, Le-Qun; Jacqz-Aigrain, Evelyne; Zhao, Wei
作者机构:[Hao, Guo-Xiang; Zhao, Wei] Shandong Univ, Sch Pharmaceut Sci, Dept Clin Pharm, Jinan, Peoples R China.; [Song, Lin-Lin; Su, Le-Qun; Zhao, Wei] Shan 更多
通讯作者:Zhao, W
通讯作者地址:[Zhao, W]Shandong Univ Jinan, Sch Pharmaceut Sci, Jinan 250012, Peoples R China.
来源:BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
出版年:2020
卷:86
期:2
页码:274-284
DOI:10.1111/bcp.14174
关键词:children; glomerular disease; tacrolimus
摘要:Glomerular diseases are leading causes of end-stage renal disease in children. Tacrolimus is frequently used off-label in the treatment of glomerular diseases. The effectiveness, safety and pharmacokinetic data of tacrolimus in the treatment of glomerular diseases in children are reviewed in this paper to provide evidence to support its rational use in clinical practice. The remission rates in previously published studies were different. In 19 clinical trials on children with nephrotic syndrome, the overall remission rate was 52.6-97.6%. In four clinical trials on children with lupus nephritis, the overall remission rate was 81.8-89.5%. In a pilot study with paediatric Henoch-Schonlein purpura nephritis patients, the overall remission rate was 100.0%. Infection, nephrotoxicity, gastrointestinal symptoms and hypertension are the most common adverse events. Body weight, age, CYP3A5 genotype, cystatin-C and daily dose of tacrolimus may have significant effects on the pharmacokinetics of tacrolimus in children with glomerular disease. More prospective controlled trials with long follow-up are needed to demonstrate definitely the effectiveness, safety and pharmacokinetics of tacrolimus in children with glomerular diseases.
收录类别:SCOPUS;SCIE
资源类型:期刊论文
原文链接:https://www.scopus.com/inward/record.uri?eid=2-s2.0-85078031956&doi=10.1111%2fbcp.14174&partnerID=40&md5=73db965a329903d18e3dc5a95c12292f
TOP